Omeros Corp
Suletud
Sektor Tervishoid
4.05 0.75
Ülevaade
Aktsiahinna muutus
24h
Min
4.03
Max
4.08
Sissetulek | -56M |
|---|---|
Aktsiakasum | -0.15 |
Järgmine tulemuste avaldamine | 7. nov 2024 |
|---|
Turukapital | -9.5M 216M |
|---|---|
Eelmine avamishind | 3.3 |
Eelmine sulgemishind | 4.05 |
Uudiste sentiment
By Acuity
58%
42%
313 / 390 Pingereas Healthcare
Tehniline skoor
By Trading Central
Kindlus
Strong Bearish Evidence
Omeros Corp Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Omeros Corp Prognoos
Sentiment
By Acuity
313 / 390 Pingereas Tervishoid
Uudiste sentiment
Tõusu märgid
Volatiilsus
Alla keskmise
Uudismaht (RCV)
Alla keskmise
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Omeros Corp
Omeros Corporation is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers. Its lead drug product OMIDRIA (phenylephrine and ketorolac intraocular solution) is used during cataract surgery or intraocular lens replacement for adult and pediatric patients. Its drug candidate narsoplimab is the subject of a biologics license application (BLA) for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). It also has multiple Phase III and Phase II clinical-stage development programs in its pipeline, which are focused on complement-mediated disorders, including immunoglobulin A (IgA) nephropathy, atypical hemolytic uremic syndrome (aHUS) and COVID-19.
